Health care giant Johnson & Johnson (NYSE: JNJ) reported second-quarter earnings this morning, posting adjusted earnings per share (EPS) of $1.30 on revenue of $16.5 billion. The consensus estimate from analysts called for EPS of $1.29 on revenue of $16.7 billion. Including one-time charges related to acquisition costs, litigation and other charges, J&J posted EPS of $0.50. Currency exchange rates lowered quarterly revenue by 4.2%.
The worse news from J&J is that the company cut its full-year adjusted EPS forecast from a range of $5.07 to $5.17 to one of $5.00 to $5.07. The revised guidance “reflects the negative impact of recent currency movements, partially offset by the positive contribution from the Synthes acquisition.” J&J’s $19.7 billion purchase of orthopedic device maker Synthes closed in the second quarter.
The effect of a stronger dollar hit J&J hard, costing the company’s consumer division 5.2% of revenue, and international sales a negative impact of 8%. Currency impacts also hit the medical devices and diagnostics group, lowering global sales by 3.5% and international sales by 6.2%.
J&J shares are up about 0.3% in pre-market trading at $68.67 in a 52-week range of $59.08 to $68.74.
Paul Ausick
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
